Bavarian Nordic A/S (OTCMKTS:BVNRY) Sees Significant Decrease in Short Interest

Bavarian Nordic A/S (OTCMKTS:BVNRY) was the recipient of a large drop in short interest in October. As of October 31st, there was short interest totalling 1,200 shares, a drop of 14.3% from the October 15th total of 1,400 shares. Based on an average daily trading volume, of 36,300 shares, the days-to-cover ratio is currently 0.0 days.

Bavarian Nordic A/S Trading Down 14.2 %

Shares of Bavarian Nordic A/S stock traded down $1.35 on Friday, hitting $8.13. 178,302 shares of the company traded hands, compared to its average volume of 33,515. The firm’s 50-day simple moving average is $10.78 and its 200 day simple moving average is $9.84. The company has a market cap of $1.92 billion, a P/E ratio of 18.48 and a beta of 1.71. Bavarian Nordic A/S has a 12-month low of $6.84 and a 12-month high of $14.60.

Bavarian Nordic A/S (OTCMKTS:BVNRY) last posted its quarterly earnings data on Thursday, August 22nd. The company reported $0.16 earnings per share for the quarter. The firm had revenue of $205.99 million for the quarter. Bavarian Nordic A/S had a net margin of 11.50% and a return on equity of 12.50%. Analysts predict that Bavarian Nordic A/S will post 0.57 earnings per share for the current year.

Bavarian Nordic A/S Company Profile

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.